{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:27:54Z","timestamp":1793734074121,"version":"4.6.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Despite advances in treatments, multiple myeloma (MM) remains an incurable cancer where relapse is common. We developed a circulating tumor DNA (ctDNA) approach in order to characterize tumor genomics, monitor treatment response, and detect early relapse in MM. By sequencing 412 specimens from 64 patients with newly diagnosed or relapsed\/refractory disease, we demonstrate the correlation between ctDNA and key clinical biomarkers, as well as patient outcomes. We further extend our approach to simultaneously track CAR-specific cell-free DNA (CAR-cfDNA) in patients undergoing anti-BCMA CAR T-cell (BCMA-CAR) therapy. We demonstrate that ctDNA levels following BCMA-CAR inversely correlate with relative time to progression (TTP), and that measurable residual disease (MRD) quantified by peripheral blood ctDNA (ctDNA-MRD) was concordant with clinical bone marrow MRD. Finally, we show that ctDNA-MRD can anticipate clinical relapse and identify the emergence of genomically-defined therapy-resistant clones. These findings suggest multiple clinical uses of ctDNA for MM in molecular characterization and disease surveillance.<\/jats:p>","DOI":"10.1038\/s41467-025-56486-6","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T21:01:04Z","timestamp":1740085264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma"],"prefix":"10.1038","volume":"16","author":[{"given":"Hitomi","family":"Hosoya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9993-9787","authenticated-orcid":false,"given":"Mia","family":"Carleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailee","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Sworder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriya","family":"Syal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Sahaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6631-481X","authenticated-orcid":false,"given":"Alisha M.","family":"Maltos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Stehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna","family":"Hovanky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2692-3906","authenticated-orcid":false,"given":"George","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Iberri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-4305","authenticated-orcid":false,"given":"David","family":"Miklos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Khodadoust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6382-4651","authenticated-orcid":false,"given":"David M.","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"56486_CR1","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar, S. K. et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28, 1122\u20131128 (2014).","journal-title":"Leukemia"},{"key":"56486_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/10428194.2020.1827253","volume":"62","author":"M Braunlin","year":"2021","unstructured":"Braunlin, M., Belani, R., Buchanan, J., Wheeling, T. & Kim, C. Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011\u20132019 oncology clinic electronic health record data. Leuk. Lymphoma 62, 377\u2013386 (2021).","journal-title":"Leuk. Lymphoma"},{"key":"56486_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","volume":"36","author":"M Binder","year":"2022","unstructured":"Binder, M. et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia 36, 801\u2013808 (2022).","journal-title":"Leukemia"},{"key":"56486_CR4","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1038\/s41375-021-01250-0","volume":"35","author":"J Corre","year":"2021","unstructured":"Corre, J. et al. Improved survival in multiple myeloma during the 2005\u20132009 and 2010\u20132014 periods. Leukemia 35, 3600\u20133603 (2021).","journal-title":"Leukemia"},{"key":"56486_CR5","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-10-1843","volume":"17","author":"NC Munshi","year":"2011","unstructured":"Munshi, N. C. & Avet-Loiseau, H. Genomics in multiple myeloma. Clin. Cancer Res. 17, 1234\u20131242 (2011).","journal-title":"Clin. Cancer Res."},{"key":"56486_CR6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2017","unstructured":"Manier, S. et al. Genomic complexity of multiple myeloma and its clinical implications. Nat. Rev. Clin. Oncol. 14, 100\u2013113 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"56486_CR7","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.1016\/j.clml.2018.06.028","volume":"18","author":"UH Patel","year":"2018","unstructured":"Patel, U. H., Drabick, J. J., Malysz, J. & Talamo, G. Nonsecretory and light chain escape in patients with multiple myeloma. Clin. Lymphoma Myeloma Leuk. 18, e515\u2013e519 (2018).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"56486_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrc.2017.63","volume":"17","author":"C Pawlyn","year":"2017","unstructured":"Pawlyn, C. & Morgan, G. J. Evolutionary biology of high-risk multiple myeloma. Nat. Rev. Cancer 17, 543\u2013556 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"56486_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"56486_CR10","doi-asserted-by":"publisher","first-page":"8031","DOI":"10.1200\/JCO.2023.41.16_suppl.8031","volume":"41","author":"K Desai","year":"2023","unstructured":"Desai, K. et al. Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class\u2013exposed (TCE) relapsed and refractory multiple myeloma (RRMM). J. Clin. Oncol. 41, 8031 (2023).","journal-title":"J. Clin. Oncol."},{"key":"56486_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00296-y","volume":"8","author":"L Rasche","year":"2017","unstructured":"Rasche, L. et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat. Commun. 8, 268 (2017).","journal-title":"Nat. Commun."},{"key":"56486_CR12","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","volume":"36","author":"DM Kurtz","year":"2018","unstructured":"Kurtz, D. M. et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J. Clin. Oncol. 36, 2845\u20132853 (2018).","journal-title":"J. Clin. Oncol."},{"key":"56486_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1158\/1078-0432.CCR-22-1654","volume":"29","author":"I Fern\u00e1ndez-Miranda","year":"2023","unstructured":"Fern\u00e1ndez-Miranda, I. et al. Monitoring of circulating tumor DNA predicts response to treatment and early progression in follicular lymphoma: results of a prospective pilot study. Clin. Cancer Res. 29, 209\u2013220 (2023).","journal-title":"Clin. Cancer Res."},{"key":"56486_CR14","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1200\/JCO.22.00826","volume":"41","author":"JA Mutter","year":"2023","unstructured":"Mutter, J. A. et al. Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas. J. Clin. Oncol. 41, 1684\u20131694 (2023).","journal-title":"J. Clin. Oncol."},{"key":"56486_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.786451","volume":"12","author":"B Dhakal","year":"2022","unstructured":"Dhakal, B. et al. Assessment of molecular residual disease using circulating tumor DNA to identify multiple myeloma patients at high risk of relapse. Front Oncol. 12, 786451 (2022).","journal-title":"Front Oncol."},{"key":"56486_CR16","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1038\/leu.2016.366","volume":"31","author":"S Mithraprabhu","year":"2017","unstructured":"Mithraprabhu, S. et al. Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma. Leukemia 31, 1695\u20131705 (2017).","journal-title":"Leukemia"},{"key":"56486_CR17","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1038\/s41375-018-0115-z","volume":"32","author":"G Guo","year":"2018","unstructured":"Guo, G. et al. Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia 32, 1838\u20131841 (2018).","journal-title":"Leukemia"},{"key":"56486_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04001-5","volume":"9","author":"S Manier","year":"2018","unstructured":"Manier, S. et al. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat. Commun. 9, 1691 (2018).","journal-title":"Nat. Commun."},{"key":"56486_CR19","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.3324\/haematol.2017.184358","volume":"103","author":"B Gerber","year":"2018","unstructured":"Gerber, B. et al. Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. Haematologica 103, e245\u2013e248 (2018).","journal-title":"Haematologica"},{"key":"56486_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15086","volume":"8","author":"O Kis","year":"2017","unstructured":"Kis, O. et al. Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. Nat. Commun. 8, 15086 (2017).","journal-title":"Nat. Commun."},{"key":"56486_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.clml.2013.09.013","volume":"14","author":"R Vij","year":"2014","unstructured":"Vij, R. et al. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients. Clin. Lymphoma Myeloma Leuk. 14, 131\u2013139.e131 (2014).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"56486_CR22","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1182\/bloodadvances.2018025197","volume":"2","author":"C Mazzotti","year":"2018","unstructured":"Mazzotti, C. et al. Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv. 2, 2811\u20132813 (2018).","journal-title":"Blood Adv."},{"key":"56486_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1053\/j.seminhematol.2018.03.002","volume":"55","author":"TJ Pugh","year":"2018","unstructured":"Pugh, T. J. Circulating tumour DNA for detecting minimal residual disease in multiple myeloma. Semin Hematol. 55, 38\u201340 (2018).","journal-title":"Semin Hematol."},{"key":"56486_CR24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med 20, 548\u2013554 (2014).","journal-title":"Nat. Med"},{"key":"56486_CR25","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nbt.3520","volume":"34","author":"AM Newman","year":"2016","unstructured":"Newman, A. M. et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat. Biotechnol. 34, 547\u2013555 (2016).","journal-title":"Nat. Biotechnol."},{"key":"56486_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker, B. A. et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 132, 587\u2013597 (2018).","journal-title":"Blood"},{"key":"56486_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli, N. et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun. 5, 2997 (2014).","journal-title":"Nat. Commun."},{"key":"56486_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr, J. G. et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91\u2013101 (2014).","journal-title":"Cancer Cell"},{"key":"56486_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467\u2013472 (2011).","journal-title":"Nature"},{"key":"56486_CR30","doi-asserted-by":"publisher","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","volume":"8","author":"F Scherer","year":"2016","unstructured":"Scherer, F. et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci. Transl. Med. 8, 364ra155 (2016).","journal-title":"Sci. Transl. Med."},{"key":"56486_CR31","doi-asserted-by":"publisher","unstructured":"Kurtz, D. M. et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-021-00981-w (2021).","DOI":"10.1038\/s41587-021-00981-w"},{"key":"56486_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7997","volume":"6","author":"BA Walker","year":"2015","unstructured":"Walker, B. A. et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat. Commun. 6, 6997 (2015).","journal-title":"Nat. Commun."},{"key":"56486_CR33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1053\/j.gastro.2019.10.039","volume":"158","author":"TD Azad","year":"2020","unstructured":"Azad, T. D. et al. Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer. Gastroenterology 158, 494\u2013505.e496 (2020).","journal-title":"Gastroenterology"},{"key":"56486_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","volume":"580","author":"JJ Chabon","year":"2020","unstructured":"Chabon, J. J. et al. Integrating genomic features for non-invasive early lung cancer detection. Nature 580, 245\u2013251 (2020).","journal-title":"Nature"},{"key":"56486_CR35","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","volume":"41","author":"BJ Sworder","year":"2023","unstructured":"Sworder, B. J. et al. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell 41, 210\u2013225.e215 (2023).","journal-title":"Cancer Cell"},{"key":"56486_CR36","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1182\/blood-2019-129155","volume":"134","author":"C Chakraborty","year":"2019","unstructured":"Chakraborty, C. et al. Recurrent non-coding mutations in BCL7A may have significant functional consequence in multiple myeloma. Blood 134, 857 (2019).","journal-title":"Blood"},{"key":"56486_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1182\/blood-2018-190","volume":"132","author":"MK Samur","year":"2018","unstructured":"Samur, M. K. et al. Landscape of recurrent mutations in non-coding genome with functional implications in newly-diagnosed multiple myeloma. Blood 132, 190 (2018).","journal-title":"Blood"},{"key":"56486_CR38","doi-asserted-by":"publisher","first-page":"24779","DOI":"10.1073\/pnas.1914163116","volume":"116","author":"JC Shen","year":"2019","unstructured":"Shen, J. C. et al. A high-resolution landscape of mutations in the. Proc. Natl Acad. Sci. USA 116, 24779\u201324785 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"56486_CR39","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker, B. A. et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J. Clin. Oncol. 33, 3911\u20133920 (2015).","journal-title":"J. Clin. Oncol."},{"key":"56486_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson, V. A. et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat. Commun. 8, 1324 (2017).","journal-title":"Nat. Commun."},{"key":"56486_CR41","doi-asserted-by":"publisher","first-page":"10712","DOI":"10.1182\/blood-2022-167900","volume":"140","author":"A Palomino Mosquera","year":"2022","unstructured":"Palomino Mosquera, A. et al. Accurate detection of clinically actionable copy number variants in diverse hematological neoplasms by routine targeted sequencing: a comparative performance study. Blood 140, 10712\u201310713 (2022).","journal-title":"Blood"},{"key":"56486_CR42","doi-asserted-by":"publisher","unstructured":"Wang, X. et al. PEcnv: accurate and efficient detection of copy number variations of various lengths. Brief Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbac375 (2022).","DOI":"10.1093\/bib\/bbac375"},{"key":"56486_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1182\/blood-2020-136865","volume":"136","author":"D Auclair","year":"2020","unstructured":"Auclair, D. et al. A next generation liquid biopsy approach for multiple myeloma. Blood 136, 33 (2020).","journal-title":"Blood"},{"key":"56486_CR44","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1111\/bjh.16440","volume":"189","author":"X Long","year":"2020","unstructured":"Long, X. et al. The utility of non-invasive liquid biopsy for mutational analysis and minimal residual disease assessment in extramedullary multiple myeloma. Br. J. Haematol. 189, e45\u2013e48 (2020).","journal-title":"Br. J. Haematol."},{"key":"56486_CR45","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/ejh.13541","volume":"106","author":"S Deshpande","year":"2021","unstructured":"Deshpande, S. et al. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. Eur. J. Haematol. 106, 230\u2013240 (2021).","journal-title":"Eur. J. Haematol."},{"key":"56486_CR46","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","volume":"2","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk, N. W. C. J., Themeli, M. & Usmani, S. Z. Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma. Blood Cancer Discov. 2, 302\u2013318 (2021).","journal-title":"Blood Cancer Discov."},{"key":"56486_CR47","doi-asserted-by":"publisher","unstructured":"Lee, H. et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-023-02491-5 (2023).","DOI":"10.1038\/s41591-023-02491-5"},{"key":"56486_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur, M. K. et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat. Commun. 12, 868 (2021).","journal-title":"Nat. Commun."},{"key":"56486_CR49","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Via","year":"2021","unstructured":"Da Via, M. C. et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat. Med. 27, 616\u2013619 (2021).","journal-title":"Nat. Med."},{"key":"56486_CR50","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s12185-014-1514-1","volume":"99","author":"N Sekiguchi","year":"2014","unstructured":"Sekiguchi, N. et al. Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib\/dexamethasone therapy. Int J. Hematol. 99, 288\u2013295 (2014).","journal-title":"Int J. Hematol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56486-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56486-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56486-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T21:52:57Z","timestamp":1740088377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56486-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["56486"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-56486-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"6 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.J.S.: consultancy: Foresight Diagnostics. M.L.: advisory board\/consulting for Janssen, BMS, and Kite. D.M.: patent: Pharmacyclics supporting ibrutinib for chronic graft-vs-host disease. Research funding and consultancy: Pharmacyclics, Kite Pharma, Adaptive Biotechnologies, Novartis, Juno Therapeutics, Celgene, Janssen Pharmaceuticals, Roche, Genentech, Precision Bioscience, Allogene and Miltenyi Biotec. M.S.K: research funding: Nutcracker Therapeutics, CRISPR Therapeutics; Consultancy: Daiichi Sankyo, Myeloid Therapeutics. S.S.: research funding: Magenta Therapeutics, BMS, Allogene, Janssen; Consultancy: Magenta Therapeutics, BMS, Janssen, Sanofi, Oncopeptides, Takeda. D.M.K.: patents: D.M.K. reports issued patents pertaining to ctDNA-MRD detection assigned to Stanford University and licensed to Foresight Diagnostics. Consultancy: Foresight Diagnostics, Roche, Genentech, and Adaptive Biotechnologies. Stock and Equity Ownership: D.M.K. reports equity ownership in Foresight Diagnostics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1824"}}